Prokidney (PROK) Cash & Equivalents (2021 - 2026)

Prokidney (PROK) has 6 years of Cash & Equivalents data on file, last reported at $101.9 million in Q1 2026.

• Quarterly Cash & Equivalents rose 4.18% year-over-year to $101.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $101.9 million (up 4.18% YoY) and the FY2025 annual result came in at $108.5 million, up 9.5% from the prior year.
• Cash & Equivalents retreated to $101.9 million in Q1 2026 per PROK's latest filing, from $108.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $506.3 million in Q3 2022 and bottomed at $60.6 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $108.1 million (2024), against an average of $183.9 million.
• The widest annual swing landed in 2022, when Cash & Equivalents jumped 2284.73%; it then tumbled 87.63% in 2023.
• Tracing PROK's Cash & Equivalents over 5 years: stood at $490.3 million in 2022, then plunged by 87.63% to $60.6 million in 2023, then soared by 63.43% to $99.1 million in 2024, then climbed by 9.5% to $108.5 million in 2025, then slipped by 6.12% to $101.9 million in 2026.
• Per Business Quant, the three latest PROK Cash & Equivalents figures stand at $101.9 million (Q1 2026), $108.5 million (Q4 2025), and $95.3 million (Q3 2025).

Peer Comparison